Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, Reuters quoted the Sunday Times report. Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year, sooner than previously anticipated. More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic and governments are racing to secure supplies of vaccines even before their efficacy is proven. A supply agreement with Sanofi and GSK would be Britain's second such deal, after it said it would buy 100 million doses of the Oxford-AstraZeneca vaccine.
